Jazz二季度收入创新高并上调全年收入指引但稿件为已处理财报催化重复扩散

Trump insists Iran talks ongoing, says Hormuz could open ’literally by tomorrow’
Introduction & Market Context
Jazz Pharmaceuticals (NASDAQ:JAZZ) presented its second-quarter 2026 financial results on August 3, revealing record quarterly revenue of $1.208 billion and raising full-year guidance despite missing Wall Street expectations on earnings and revenue. The company’s shares rose 3.74% in after-hours trading to $261, approaching the 52-week high of $261.30, as investors focused on the strength of the underlying business and the imminent regulatory decision for zanidatamab in gastric cancer.
The presentation, themed "Redefining Possibilities in Rare Disease," highlighted broad-based momentum across the company’s sleep, epilepsy, and oncology franchises, with management expressing high confidence in an August 25 PDUFA approval for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma.
Quarterly Performance Highlights
As shown in the following comprehensive overview of second-quarter execution, Jazz delivered double-digit growth across its core therapeutic areas while advancing multiple pipeline programs.
The company reported total revenues of $1.208 billion, representing 16% year-over-year growth from the $1.046 billion recorded in the second quarter of 2025. This marked a record quarterly performance, driven primarily by strong execution in Xywav, Epidiolex, and the oncology portfolio.
Non-GAAP adjusted earnings per share came in at $5.71, which included $0.94 in acquired in-process research and development charges. While this figure missed analyst expectations of $6.18, the company maintained a robust non-GAAP gross margin of 92.1% and generated $824 million in operating cash flow during the first half of 2026.
The company’s balance sheet remained strong with $2.2 billion in cash at quarter-end, providing substantial financial flexibility for business development and pipeline advancement.
Commercial Execution: Sleep and Epilepsy Franchises
Jazz’s rare sleep franchise demonstrated continued strength, with Xywav posting 13% year-over-year revenue growth and adding 525 net patients during the quarter. The following chart illustrates the steady patient growth trajectory across both narcolepsy and idiopathic hypersomnia indications.
Total net active Xywav patients reached 17,125 at the end of the second quarter, up 12% from 15,225 patients in the prior-year period. The growth was balanced between the established narcolepsy indication, which grew to 11,275 patients, and the newer idiopathic hypersomnia indication, which expanded to 5,850 patients with 325 net patient additions in the quarter.
Management attributed Xywav’s performance to its differentiated low-sodium profile and individualized dosing, which continue to resonate with healthcare providers and patients. The product maintains its position as the number one branded treatment in narcolepsy, while investments in idiopathic hypersomnia are driving positive momentum. The company expects total rare sleep revenue of $2.025 billion to $2.125 billion for full-year 2026.
In the epilepsy franchise, Epidiolex demonstrated strong commercial momentum with 16% year-over-year growth, as illustrated in the following revenue comparison.
Epidiolex generated $292 million in net product sales during the second quarter, up from $252 million in the prior-year period, maintaining its position as the number one branded epilepsy treatment. The company is pursuing multiple growth opportunities, including the recent submission of a new drug application for a cannabidiol capsule formulation designed to broaden utilization and increase patient flexibility.
Additional data generation efforts include beyond-seizure benefits from the EpiCom study in tuberous sclerosis complex and nurse-reported responses from the BECOME caregiver survey in long-term care facilities. The JazzCares suite of services, including a Nurse Navigator program, continues to support patient access and adherence.
Oncology Portfolio Expansion
The oncology franchise delivered particularly strong performance, with revenues up 32% year-over-year, led by Zepzelca, the newly launched Modeyso, and Ziihera. The company’s most significant near-term opportunity lies with zanidatamab, which is positioned to become a cornerstone HER2-targeted therapy across multiple cancer types.
The following overview illustrates the breadth of zanidatamab’s potential across biliary tract cancer, gastroesophageal adenocarcinoma, breast cancer, and other HER2-expressing tumors.
Jazz has prepared for an immediate launch of zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, with a customer-facing team in place ahead of the August 25, 2026 PDUFA date. The product has received FDA Breakthrough Therapy designation and aims to become the new standard of care for patients with first-line HER2-positive GEA, regardless of PD-L1 status.
The GEA opportunity represents approximately 63,000 cases annually in the U.S., Europe, and Japan. Beyond GEA, zanidatamab holds conditional marketing authorization from the European Commission for second-line HER2-positive biliary tract cancer, with a confirmatory first-line trial ongoing in a market of approximately 12,000 annual cases.
In breast cancer, the company is advancing multiple trials including the Phase 3 EmpowHER-BC-303 study in patients post-trastuzumab deruxtecan, with data expected in late 2027 or early 2028. The breast cancer opportunity spans approximately 150,000 cases annually across major markets.
The company’s launch strategy for GEA focuses on four critical pillars, as shown in the following execution framework.
The launch approach emphasizes clinical education to establish Ziihera plus tislelizumab as the new standard of care, accelerated market access leveraging an established permanent J-code to eliminate reimbursement barriers, day-one mobilization of cross-functional commercial teams, and seamless patient onboarding through comprehensive JazzCares support services.
Modeyso, approved for recurrent H3 K27M-mutant diffuse midline glioma, demonstrated strong early uptake with more than 600 patients treated as of June 30, 2026. The following illustration shows the phased approach to Modeyso’s market introduction.
The product generated $48 million in net product sales during the second quarter, exceeding initial expectations. As the first and only FDA-approved treatment for this aggressive form of glioma, Modeyso addresses a significant unmet need in a condition with median overall survival of less than six months after recurrence. The company sees peak U.S. sales potential exceeding $500 million.
Zepzelca continued its strong growth trajectory, posting 42% year-over-year revenue growth driven by uptake in the first-line maintenance extensive-stage small cell lung cancer indication, as shown in the following sales progression.
Second-quarter net product sales reached $106 million, up from $75 million in the prior-year period. The product received FDA approval for first-line maintenance therapy in combination with Tecentriq during the fourth quarter of 2025 and has been included in NCCN Guidelines as a Category 1 preferred regimen. Clinical data from the IMforte trial showed median overall survival of 13.2 months for Zepzelca versus 10.6 months for atezolizumab alone from the point of randomization.
Management indicated that commercial efforts are primarily focused on the first-line maintenance setting, and the company plans to submit a labeling supplement in the third quarter of 2026 to remove the second-line indication based on Phase 3 LAGOON trial results, in alignment with FDA feedback.
Pipeline Progress and Clinical Data
The most significant pipeline development during the quarter was the publication of zanidatamab’s Phase 3 HERIZON-GEA-01 trial results in The New England Journal of Medicine. The following Kaplan-Meier curves illustrate the overall survival benefit demonstrated in the study.
The trial showed that zanidatamab plus tislelizumab plus chemotherapy achieved a median overall survival of 26.4 months compared to 19.2 months for the control arm of trastuzumab plus chemotherapy, representing a 7-month improvement. The hazard ratio of 0.72 with a p-value of 0.0043 demonstrated statistical significance, and the benefit was observed regardless of PD-L1 status.
A second analysis comparing zanidatamab plus chemotherapy (without tislelizumab) to the control arm showed median overall survival of 24.4 months versus 19.2 months, with a hazard ratio of 0.80 and p-value of 0.0564. These data have been submitted for potential inclusion in NCCN Guidelines and support zanidatamab’s positioning as the HER2-targeted agent of choice in first-line HER2-positive GEA.
The company’s broader pipeline continues to advance across multiple programs, as illustrated in the following development timeline.
Key upcoming milestones include interim overall survival data from the HERIZON-GEA-01 trial expected in the third quarter of 2026, interim overall survival data from the ACTION trial of dordaviprone in first-line H3 K27M-mutant diffuse glioma expected in the first half of 2027, and top-line data from the EmpowHER-BC-303 breast cancer trial anticipated in late 2027 or early 2028.
The company also announced a collaboration with AbCellera to discover next-generation T-cell engager multispecific antibodies, expanding its oncology innovation capabilities. In epilepsy, Jazz submitted a new drug application for a cannabidiol oral capsule formulation and initiated new clinical trials in developmental and epileptic encephalopathy and juvenile myoclonic epilepsy.
Financial Outlook and Raised Guidance
Based on first-half performance and confidence in execution, Jazz raised its full-year 2026 revenue guidance, as detailed in the following updated forecast.
The company now expects total revenues of $4.60 billion to $4.75 billion, up significantly from prior guidance of $4.25 billion to $4.50 billion. Management attributed the upward revision primarily to outstanding execution by Xywav field teams, with the company now expecting double-digit growth for Xywav sales and combined rare oncology plus epilepsy revenue.
Non-GAAP gross margin guidance remained unchanged at 90% to 91%, while selling, general and administrative expenses are expected to increase to $1.33 billion to $1.37 billion, reflecting targeted investments to drive further growth of Xywav and Epidiolex and to build key commercial capabilities. Research and development expenses are projected at $725 million to $775 million, unchanged from prior guidance, as the company advances zanidatamab and other clinical programs.
The non-GAAP effective tax rate is expected to range from 11.5% to 13.5%, and weighted-average diluted shares outstanding are projected at 69 million to 70 million, up from prior guidance of 66 million to 67 million due to the effect of higher stock prices on convertible notes and employee stock compensation plans.
The following detailed financial results table provides a comprehensive view of second-quarter performance metrics.
Non-GAAP selling, general and administrative expenses increased 11% year-over-year to $343.2 million, driven by investments in Modeyso and zanidatamab first-line GEA launch preparation, as well as building key commercial capabilities. Non-GAAP research and development expenses rose 11% to $184.9 million, primarily due to higher clinical study costs related to zanidatamab trials.
The non-GAAP effective tax rate was 15.8% in the second quarter of 2026, compared to negative 9.1% in the prior-year period, with the current quarter reflecting changes in the expected geographic mix of income and expenses. Weighted-average diluted shares increased to 69.4 million from 61.2 million, including the accounting effect of higher stock prices on employee stock compensation plans and convertible notes.
Strategic Positioning and Business Development
Jazz’s strategic focus remains centered on expanding leadership in rare disease therapeutic areas and advancing differentiated innovation. The following summary illustrates the company’s momentum entering the second half of 2026.
In research and development, the company is positioned to capitalize on zanidatamab’s near-term launch opportunity in GEA while advancing multiple trials in breast cancer and other HER2-expressing tumors. The dordaviprone ACTION trial in first-line diffuse glioma represents another potential value driver with data expected in the first half of 2027.
On the commercial front, continued execution with Epidiolex and Xywav, combined with a full year of Modeyso and Zepzelca first-line maintenance sales in 2026, provides a diversified revenue base. Management emphasized that the company is actively identifying and pursuing business development opportunities in rare disease to drive long-term growth and value creation.
The company’s strong balance sheet, with $2.2 billion in cash and $824 million in year-to-date operating cash flow, provides substantial capacity for strategic transactions. During the earnings call, executives indicated they expect to announce one or more business development deals in 2026, focusing on areas where Jazz has established commercial and scientific expertise in rare disease.
Forward-Looking Statements
Near-term catalysts include the August 25, 2026 PDUFA decision for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, where management expressed high confidence in approval. The company also expects to report a second interim overall survival analysis for zanidatamab’s doublet arm during the third quarter of 2026.
The planned third-quarter 2026 submission to remove Zepzelca’s second-line indication, based on Phase 3 LAGOON trial results and in alignment with FDA guidance, will streamline the product’s label to focus on the first-line maintenance opportunity where clinical differentiation is strongest.
Looking further ahead, the Modeyso ACTION study interim analysis in the first half of 2027 and EmpowHER-BC-303 breast cancer trial data in late 2027 or early 2028 represent significant pipeline inflection points that could expand zanidatamab’s commercial opportunity and validate the company’s oncology strategy.
While the company faces ongoing competitive pressure in sleep medicine, including potential orexin agonist entries expected in 2028, management emphasized Xywav’s differentiated low-sodium profile and its efficacy in treating disrupted nighttime sleep as durable competitive advantages. The diversification of revenue across sleep, epilepsy, and oncology franchises, combined with a robust pipeline, positions Jazz for sustained growth in the rare disease space.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.